Research programme: cell therapies - LIfT Biosciences
Alternative Names: AMR/Other - LIfT BiosciencesLatest Information Update: 16 Jan 2026
At a glance
- Originator LIfT Biosciences
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Infections; Unspecified
Most Recent Events
- 16 Jan 2026 Discontinued for Infections in United Kingdom (Parenteral) (LIfT Biosciences pipeline, January 2026)
- 16 Jan 2026 Discontinued for Unspecified in United Kingdom (Parenteral) (LIfT Biosciences pipeline, January 2026)
- 19 Jul 2023 Early research in Infections in United Kingdom (Parenteral) before July 2023 (LIfT Biosciences pipeline, July 2023)